(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanamide
• 化学式: C₁₆H₂₃N₃O₃
• 分子量: 305.37
• InChiKey: FXZBGLHWVMPHPY-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] THERAPEUTIC METHODS FOR TREATING SOLID TUMORS AND RELATED DIAGNOSTIC METHODS<br/>[FR] MÉTHODES DE TRAITEMENT DES TUMEURS SOLIDES ET MÉTHODES DE DIAGNOSTIC ASSOCIÉES
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2014144858A1

  公开（公告）日：2014-09-18

  The present invention provides a method for treating a subject afflicted with a cancer which comprises administering to the subject (i) a proteasome antagonist and (ii) a PI3K signal transduction pathway antagonist, each of (i) and (ii) in an amount such that when both (i) and (ii) are administered, the administration is effective to treat the subject. The present invention also provides a method for treating a subject afflicted with a cancer which comprises administering to the subject (i) a proteasome antagonist, and (ii) an oligonucleotide which decreases the amount of PI3K,mTor, TORC1, TORC2, AKT, or JNK produced by cells of the cancer. The present invention provides processes for identifying whether a compound is an epithelial cancer drug candidate. The present invention also provides a method for identifying a cancer patient who will likely benefit from treatment with a PI3K signal transduction pathway antagonist.
• [EN] CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB<br/>[FR] CO-CRISTAL DE CARFILZOMIB AVEC DE L'ACIDE MALÉIQUE ET PROCÉDÉ POUR LA PRÉPARATION DE CARFILZOMIB PUR
  申请人：REDDYS LAB LTD DR

  公开号：WO2016108204A1

  公开（公告）日：2016-07-07

  Aspects of the present application relates to co-crystal of carfilzomib with maleic acid, process for the preparation of co-crystal of carfilzomib with maleic acid, process for the preparation of pure carfilzomib from co-crystal of carfilzomib with maleic acid and process for the preparation of amorphous carfilzomib.